Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04231682
Other study ID # IRB-2020-300
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date July 1, 2020
Est. completion date January 1, 2025

Study information

Verified date June 2020
Source Albert Einstein Healthcare Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Organ transplant recipients are known to suffer from bone loss and subsequent fractures after the transplant operation with the most rapid bone loss occurring within the first 3-12 months. Guidelines for prevention and treatment of this serious complication are only written by individual medical societies interested in each organ (separate kidney from liver or heart transplants management) and they are based on studies done with limited medications choices. The majority of studies are done with the use of bisphosphonates, and there are very limited, or no data, on the effect of other medications used for Osteoporosis, including the use of denosumab. This study will focus on the evaluation of the efficacy and safety of denosumab 60mg use early (within first 3 months) after Liver Transplantation in the management of bone loss and prevention of fragility fractures. Different tests will be used to study the effect of the medication on the skeleton, including imaging studies as well as specific labwork.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 1, 2025
Est. primary completion date January 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age >=18 years old

- First-time Liver transplant Recipients

- All men, postmenopausal women and women with history of hysterectomy or tubal ligation

- Patients who have not been treated with medications for Osteoporosis within the past 12 months before the liver transplant

- Patients able and agreeable to follow up at out Institution for the duration of the study

- Patients hospitalized for less than 45 consecutive days after the liver transplant surgery

- Patients with GFR>30ml/min (calculated by Cockcroft-Gault equation, see Table 3 for details)

- Patients with corrected Calcium >= 8.5

- Patients with PTH intact levels WNL (as per lab values)

- Patients with vit D>=20; NOTE: patients with vit D <20 will be treated with high dose Ergocalciferol 50,000 units daily and rechecked in 2 weeks

- Patients with t-score >=-3.5 at all sites checked by DEXA scan

- Patients agree to sign an informed consent form to be in the study

- Can be treated with denosumab or placebo within 3 months from the liver transplant date

Exclusion Criteria:

- Patients with previous transplants

- Patients that are getting 2 simultaneous transplants, like combined kidney and liver transplants

- Age < 18 year old

- Patients hospitalized for over 45 days after the liver transplant surgery

- Patients with GFR< 30ml/min

- Patients with hypocalcemia defined as corrected calcium < 8.5

- Patients with extensive dental problems, previous hx of Osteonecrosis of the jaw (ONJ) and/or high risk for developing ONJ

- Patients with current Hyperthyroidism

- Patients with current Primary Hyperparathyroidism defined by the combination of elevated calcium and PTH intact levels

- Patients with severe Osteoporosis as defined by t-score <-3.5 at any site shown by DEXA scan

- Women of reproductive age without history of tubal ligation or hysterectomy

- Patients who cannot read or understand the Informed Consent Document or study instructions

- Patients with diagnosis of dementia, or otherwise unable to give informed consent

- Patients unable to follow up in our Institution for the duration of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Denosumab Injection
Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
Placebos
Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Albert Einstein Healthcare Network Amgen

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine in the intervention and control groups at 12 months. 12 months
Secondary The percentage changes in bone mass calculated by DEXA scan t-score of Femoral Neck, Total Hip and Wrist in the intervention and control groups at 12 months. 12 months
Secondary The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine, Femoral Neck, Total Hip and Wrist in the intervention and control groups at 24 months. 24 months
Secondary The vertebral and non-vertebral fracture incidence at 12 and 24 months. 12 and 24 months
Secondary The percentage changes of biochemical markers of variables of bone turnover (BSAP, CTX and PINP) from baseline to 6, 12, 18 and 24 months after 1st medication administration. 6, 12, 18 and 24 months
Secondary The percentage changes of creatinine, Calcium, Magnesium, Phosphorus, PTH intact and 25-Vit D levels from baseline to 6, 12, 18 and 24 months after the 1st medication administration. 6, 12, 18 and 24 months
Secondary The percentage of patients developing infections, rejection episodes, hospitalizations or ED visits during the study period. 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Not yet recruiting NCT06431867 - Primary Care Management of Osteoporosis in Older Women
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02566655 - Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis Phase 1
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Completed NCT02143674 - Muscle Strengthening Exercises and Global Stretching in Elderly N/A
Completed NCT01694784 - Understanding and Discouraging Overuse of Potentially Harmful Screening Tests N/A